PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-018-3532-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

PARP Inhibitors in Ovarian Cancer

2013English

Apoptosis Is Augmented in High-Grade Serous Ovarian Cancer by the Combined Inhibition of BCL-2/BCL-xL and PARP

International Journal of Oncology
Cancer ResearchOncology
2017English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Low-Stage High-Grade Serous Ovarian Carcinomas

International Journal of Gynecological Pathology
GynecologyForensic MedicinePathologyObstetrics
2016English

Proteome Profiling of Low Grade Serous Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2019English

Targeting IDH1 as a Pro-Senescent Therapy in High-Grade Serous Ovarian Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

Predictors of Long-Term Survival Among High-Grade Serous Ovarian Cancer Patients

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2019English

Aurora Kinase a Expression Predicts Platinum-Resistance and Adverse Outcome in High-Grade Serous Ovarian Carcinoma Patients

Journal of Ovarian Research
GynecologyOncologyObstetrics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy